Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma

M. Ebert, M. Yokoyama, M. S. Kobrin, H. Friess, M. W. Buchler, Murray Korc

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The murine double minute-2 (MDM2) gene encodes a 90 kDa protein which binds and inactivates the protein product of the p53 tumor suppressor gene. To elucidate the potential role of MDM2 in benign and malignant hyperproliferative conditions in the pancreas, we studied MDM2 expression in cultured human pancreatic cancer cells and in pancreatic tissues from normal donors, patients with pancreatic ductal adenocarcinoma and patients with chronic pancreatitis (CP). All the tested cell lines (PANC-1, COLO-357, HPAF and T3M4) expressed a 5.5 kilobase MDM2 mRNA transcript and exhibited nuclear MDM2 immunostaining. MDM2 mRNA levels were comparable in all 18 normal and 14 CP tissues for which RNA samples were available for analysis. By comparison with the normal samples, MDM2 mRNA levels were increased 6.4-fold in 8 of 12 human pancreatic cancer samples (p <0.0001). All 8 samples exhibited nuclear MDM2 immunostaining, which was also present in 24 of 37 additional pancreatic cancers. Mild MDM2 immunoreactivity was seen in only 1 of 20 CP samples and in none of the 18 normal samples. These findings indicate that MDM2 is overexpressed in a majority of pancreatic adenocarcinomas, but not in CP samples. This selective overexpression raises the possibility that MDM2 may contribute to pancreatic neoplastic transformation by interfering with the growth-suppressing activity of wild-type p53.

Original languageEnglish (US)
Pages (from-to)1279-1284
Number of pages6
JournalInternational Journal of Oncology
Volume5
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Chronic Pancreatitis
Adenocarcinoma
Pancreatic Neoplasms
Messenger RNA
Tumor Suppressor Genes
Pancreas
Proteins
Tissue Donors
RNA
Cell Line
Growth
Genes

Keywords

  • MDM2
  • northern blot
  • p53
  • pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ebert, M., Yokoyama, M., Kobrin, M. S., Friess, H., Buchler, M. W., & Korc, M. (1994). Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. International Journal of Oncology, 5(6), 1279-1284.

Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. / Ebert, M.; Yokoyama, M.; Kobrin, M. S.; Friess, H.; Buchler, M. W.; Korc, Murray.

In: International Journal of Oncology, Vol. 5, No. 6, 1994, p. 1279-1284.

Research output: Contribution to journalArticle

Ebert, M, Yokoyama, M, Kobrin, MS, Friess, H, Buchler, MW & Korc, M 1994, 'Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma', International Journal of Oncology, vol. 5, no. 6, pp. 1279-1284.
Ebert M, Yokoyama M, Kobrin MS, Friess H, Buchler MW, Korc M. Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. International Journal of Oncology. 1994;5(6):1279-1284.
Ebert, M. ; Yokoyama, M. ; Kobrin, M. S. ; Friess, H. ; Buchler, M. W. ; Korc, Murray. / Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. In: International Journal of Oncology. 1994 ; Vol. 5, No. 6. pp. 1279-1284.
@article{b30f7e4919d54ad28b1c42cef337ca5f,
title = "Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma",
abstract = "The murine double minute-2 (MDM2) gene encodes a 90 kDa protein which binds and inactivates the protein product of the p53 tumor suppressor gene. To elucidate the potential role of MDM2 in benign and malignant hyperproliferative conditions in the pancreas, we studied MDM2 expression in cultured human pancreatic cancer cells and in pancreatic tissues from normal donors, patients with pancreatic ductal adenocarcinoma and patients with chronic pancreatitis (CP). All the tested cell lines (PANC-1, COLO-357, HPAF and T3M4) expressed a 5.5 kilobase MDM2 mRNA transcript and exhibited nuclear MDM2 immunostaining. MDM2 mRNA levels were comparable in all 18 normal and 14 CP tissues for which RNA samples were available for analysis. By comparison with the normal samples, MDM2 mRNA levels were increased 6.4-fold in 8 of 12 human pancreatic cancer samples (p <0.0001). All 8 samples exhibited nuclear MDM2 immunostaining, which was also present in 24 of 37 additional pancreatic cancers. Mild MDM2 immunoreactivity was seen in only 1 of 20 CP samples and in none of the 18 normal samples. These findings indicate that MDM2 is overexpressed in a majority of pancreatic adenocarcinomas, but not in CP samples. This selective overexpression raises the possibility that MDM2 may contribute to pancreatic neoplastic transformation by interfering with the growth-suppressing activity of wild-type p53.",
keywords = "MDM2, northern blot, p53, pancreatic cancer",
author = "M. Ebert and M. Yokoyama and Kobrin, {M. S.} and H. Friess and Buchler, {M. W.} and Murray Korc",
year = "1994",
language = "English (US)",
volume = "5",
pages = "1279--1284",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Increased MDM2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma

AU - Ebert, M.

AU - Yokoyama, M.

AU - Kobrin, M. S.

AU - Friess, H.

AU - Buchler, M. W.

AU - Korc, Murray

PY - 1994

Y1 - 1994

N2 - The murine double minute-2 (MDM2) gene encodes a 90 kDa protein which binds and inactivates the protein product of the p53 tumor suppressor gene. To elucidate the potential role of MDM2 in benign and malignant hyperproliferative conditions in the pancreas, we studied MDM2 expression in cultured human pancreatic cancer cells and in pancreatic tissues from normal donors, patients with pancreatic ductal adenocarcinoma and patients with chronic pancreatitis (CP). All the tested cell lines (PANC-1, COLO-357, HPAF and T3M4) expressed a 5.5 kilobase MDM2 mRNA transcript and exhibited nuclear MDM2 immunostaining. MDM2 mRNA levels were comparable in all 18 normal and 14 CP tissues for which RNA samples were available for analysis. By comparison with the normal samples, MDM2 mRNA levels were increased 6.4-fold in 8 of 12 human pancreatic cancer samples (p <0.0001). All 8 samples exhibited nuclear MDM2 immunostaining, which was also present in 24 of 37 additional pancreatic cancers. Mild MDM2 immunoreactivity was seen in only 1 of 20 CP samples and in none of the 18 normal samples. These findings indicate that MDM2 is overexpressed in a majority of pancreatic adenocarcinomas, but not in CP samples. This selective overexpression raises the possibility that MDM2 may contribute to pancreatic neoplastic transformation by interfering with the growth-suppressing activity of wild-type p53.

AB - The murine double minute-2 (MDM2) gene encodes a 90 kDa protein which binds and inactivates the protein product of the p53 tumor suppressor gene. To elucidate the potential role of MDM2 in benign and malignant hyperproliferative conditions in the pancreas, we studied MDM2 expression in cultured human pancreatic cancer cells and in pancreatic tissues from normal donors, patients with pancreatic ductal adenocarcinoma and patients with chronic pancreatitis (CP). All the tested cell lines (PANC-1, COLO-357, HPAF and T3M4) expressed a 5.5 kilobase MDM2 mRNA transcript and exhibited nuclear MDM2 immunostaining. MDM2 mRNA levels were comparable in all 18 normal and 14 CP tissues for which RNA samples were available for analysis. By comparison with the normal samples, MDM2 mRNA levels were increased 6.4-fold in 8 of 12 human pancreatic cancer samples (p <0.0001). All 8 samples exhibited nuclear MDM2 immunostaining, which was also present in 24 of 37 additional pancreatic cancers. Mild MDM2 immunoreactivity was seen in only 1 of 20 CP samples and in none of the 18 normal samples. These findings indicate that MDM2 is overexpressed in a majority of pancreatic adenocarcinomas, but not in CP samples. This selective overexpression raises the possibility that MDM2 may contribute to pancreatic neoplastic transformation by interfering with the growth-suppressing activity of wild-type p53.

KW - MDM2

KW - northern blot

KW - p53

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0028072896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028072896&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 1279

EP - 1284

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -